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tAbstract
This paper is the second in a series of invited perspectives by four pioneers of
nuclear medicine imaging and physics. A medical physicist and a nuclear medicine
clinical specialist each take a backward look and a forward look at the contributions
of physics to nuclear medicine. Here is a backward look from a nuclear medicine
physician's perspective.
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“He who does not doubt, does not investigate, does not perceive; and he who does not
perceive, remains in blindness and error”
Al-Ghazali (1058–1111 a.c.), theologian, jurist, philosopher, cosmologist,
psychologist and mystic
The introduction of radioactive tracers to clinical medicine can be traced to the late
40 s [1-3]. From its inception, physicians and physicists made use of purposely devel-
oped detection instruments and radionuclides in order to (a) further the understanding
of the underlying mechanisms of disease in man and (b) to investigate the earliest
manifestations of pathologies. To diagnose early on and to treat if possible were mu-
tual aims of both physicians and physicists. To underline, the contribution of scientists
and physicists to the development of Nuclear Medicine has been not just major but
disruptive and of fundamental importance. The very first applications preceded the
previously mentioned by half a century (Table 1).
November 12, 1936
Visiting patients at his thyroid clinic at Mass General Hospital, the physician JH
Means, M.D., poses a most relevant question. In his mind was already the understand-
ing of the role and importance of iodine metabolism of the thyroid and the possibility
to measure it non-invasively in vivo. RE Evans, Ph.D., rose to the challenge with a sem-
inar pronouncement:
JH Means M.D.: ‘Is there a radioisiotope of iodine?’
Robley Evans, Ph.D.: Mass. Inst. Techn.: ‘We can make some’.
This seminal encounter possibly marks the development of what was to become
known as Nuclear Medicine (Table 2, Figure 1). It is the perfect example of the inter-
disciplinary thinking which was to permeate and characterise the development of this2014 Ell; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided
he original work is properly credited.
Table 1 The pioneers of nuclear medicine
1895 X-rays Wilhelm C. Roentgen German physicist 1845 to 1923
1896 Radioactivity Antoine H. Becquerel French physicist 1852 to 1908
1898 Polonium, radium,thorium Marie Sklodowska Curie French physicist 1867 to 1934
1923 Tracer principle Georg V. Hevesy Hungarian chemist 1885 to 1966
1927 Circulation times Hermann L. Blumgart German doctor 1895 to 1977
1928 Counter Johannes W. Geiger German physicist 1882 to 1945
Walther Mueller German physicist 1905 to 1979
1932 Cyclotron Ernest O. Lawrence American physicist 1901 to 1958
Ell EJNMMI Physics 2014, 1:3 Page 2 of 7
http://www.ejnmmiphys.com/content/1/1/3speciality. It also represents the ideal setup, where an identified problem, namely, the
investigation of thyroid physiopathology, led to the development of a new investigative
tool (the radionuclide). It would take many years indeed before another ‘magic bullet’
was to be identified and widely applied. If specificity is intended by such a magic bullet,
receptor ligands such as those targeting the dopamine and somatostatin receptors and
most recently those ligands targeting the misfolded amyloid protein, are good examples
of the progress achieved.
Whilst on the topic of interdisciplinarity, it is opportune to underline that not only
physicists greatly contributed to the development of Nuclear Medicine. This equally ap-
plied inter alia to engineers, chemists and radiopharmacists. Gopal Subramanian with
a degree in chemical engineering introduced 99mTc labelled phosphonates for bone
scanning; Hal Anger as an electrical engineer and biophysicist developed the Anger
gamma camera; Roger Ekins, also a biophysicist, developed the saturation analysis/
radioimmunoassay methodology (Table 3). Physicists turned physiologist developed and
emphasised the need for elegance and simplicity in quantitative measurements.
From the preceding paragraph, it is clear that fundamental discoveries spanned a
period of a century. In the space available for this short piece, it is simply not possible
to give due consideration to all those many eminent scientists who developed the field.
So I shall focus on the three seminal physics developments which fundamentally chan-
ged the practice and future of Nuclear Medicine: the introduction of the rectilinear
scanner, the development of the gamma camera and, finally, the design of the first
single-photon emission computed tomography (SPET), positron emission photography
(PET) and PET/computed tomography (CT) instruments.Table 2 The early years of nuclear medicine
1934 First radioactive 128I Enrico Fermi Italian physicist 1901 to 1954
1936 Production of 99mTc Emilio G. Segre Italian physicist 1905 to 1989
1936 First therapy with 32P John H. Lawrence American physicist 1904 to 1991
1938 Discovery of 131I Glenn Seaborg American chemist 1912 to 1999
1942 Therapy of benign thyroid disease Saul Hertz American physician 1905 to 1950
Robley D. Evans American physicist 1907 to 1995
1946 First therapy of thyroid cancer S. M. Seidlin American physician 1895 to 1955
Leo D. Marinelli American physicist 1886 to 1995
1949 First therapy of thyroid
Carcinoma in Europe Cuno Winkler German physician 1919 to 2003
Eric E. Pochin British physician 1909 to 1990
Figure 1 Glenn Seaborg (middle) and wife (left), together with the author (right) at a SNM meeting
in the late 1990s. Seaborg won the 1951 Nobel Prize for Chemistry, discovered over 100 isotopes, advised
10 Presidents of the USA and was Chairman of the USA Atomic Energy Commission for 10 years.
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radioactive tracer method. It was used early on by Norman Veal and others in mapping
the placenta, the thyroid and the pericardium. This was laborious, a manual-driven
process and rather time-consuming. It was difficult to perceive much more than the sim-
plest outlines of organs, and yet, quantitative measurements were already taking place.
The relationship between physicists and physicians has always been most interesting.
A healthy diffidence between both experts was often present and wonderfully illus-
trated from the following extract, taken from the outstanding chronology authored by
Marshall Brucer, the first President of the Society of Nuclear Medicine (USA) and
Chairman of the medical division of Oakridge Institute of Nuclear Studies from 1948
to 1962. And one can read in page 291: ‘…three months after the London meeting (the
first meeting at University College London, on 29th July 1950, where data from 131ITable 3 Twenty-five years of seminal discoveries
1951 Rectilinear scanner Benedict Cassen American physicist 1902 to 1972
1953 CBF with radio krypton Niels Lassen Danish physician 1926 to 1997
1958 Anger gamma camera Hal O. Anger American engineer 1920 to 2005
1959 Radioimmunoassay Rosalin S. Yalow American physicist 1921 to 2011
Solomon Berson Americal physician 1918 to 1972
1960 Saturation analysis Roger Ekins British biophysicist b. 1936
1962 Tc-99 m generator Paul Harper American surgeon 1915 to 2005
Katherine Lathrope American physicist 1915 to 2005
1962 SPET David Kuhl American physician b. 1929
1971 Polyphosphates Gopal Subramanian American chemist 1953 to 2000
1973 PET Michel Ter-Pogossian American physicist 1925 to 1996
Michael Phelps American biophysicist b. 1939
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destroy it. Now, for God’s sake, when will physicists learn to measure 131I uptake?’. Leo
Marinelli murmured: ‘As soon as physicians decide how much uptake is high’.
Benedict Cassen changed all this with his discovery of the rectilinear scanner in 1950.
Born in New York in 1902, he graduated in physics and mathematics from the Royal
College of Science in London in 1927. He moved to the California institute of Technol-
ogy in 1930. Imaging the thyroid, he reported first results in 1950. The radioactive
tracer method would forever be linked to imaging, for better or for worse. Single-head,
dual-head, 3-inch or 5-inch rectilinear scanners and whole-body scanners became routine
imaging instruments for 2D organ imaging and counting, dominating for some 30 years
Nuclear Medicine applications well into the late 80s, as new tracers became available.
Whilst brilliant individual scientists made major contributions to medicine, institu-
tions and or societies have a habit of getting it wrong. In the late 40 s, much debate
and thought went into what role a medical physics department should have in a hos-
pital. To quote an example: ‘…Any one radio-element investigation may be too short
lived to justify the provision by the department concerned of the best apparatus for the
job’. [4]. Whilst Cassen had already proven that this viewpoint was completely wrong,
how would Hal Anger comment on the on the previously mentioned discussion?US patent 3,011,057 in 1961
Nuclear Medicine was to change forever with the mentioned patent, defining the Anger
gamma camera. It is truly astonishing that this technology, still in worldwide use today, has
outlived over half a century of technological breakthroughs and progress! In modern times,
there is probably no other example of such a long lasting instrumentation breakthrough.
Hal Oscar Anger (Figure 2) was born on the 20th of May 1920, in Denver, USA. He
graduated as an electrical engineer. His innovative career spanned from radar jamming
equipment to radiation detector devices, culminating with his seminal invention of theFigure 2 Hal Oscar Anger (1920 to 2005).
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Society of Nuclear Medicine and led to an explosion of commercial exploitations. The
history of the patent itself would merit a separate chapter. He died on October 21,
2005, in Berkeley. No writings can give sufficient justice to Anger's innovative genius
and the impact he has had worldwide on millions of patients investigated with his seminal
instrument.
It would take some 30 years before 3D Imaging became an integral part of the devel-
opment of Nuclear Medicine. And one has to give proper due to a medical scientist,
David Kuhl (Figure 3), the originator of single-photon emission tomography. Born in
St. Louis, Missouri in 1929, David E. Kuhl graduated in medicine at UPENN in 1955.
In 1964, David Kuhl and Roy Edwards developed the Mark II emission tomographic
scanner, starting the field of cross-sectional tomographic imaging. Kuhl went to develop
the technique of SPET - truly ahead of its time and ahead of the development of the
CT scanner (1973). Should one write a history of missed Nobel awardees? Mark II was
followed by Mark IV and a number of subsequent improvements.
Single-slice SPET imaging was subsequently superseded by whole-volume SPET
imaging, with the introduction of the rotating gamma camera (Anger's device, shaping
de novo the clinical applications of the radioactive tracer method). Without SPET, nuclear
cardiology, and less so, neurotransmission imaging would have not risen to the clinical
pre-eminence these modalities reached in the last 15 years. SPET became a truly world-
wide available technology, supported by a range of useful radiopharmaceuticals.Modern technologies (SPET, SPET/CT, PET, PET/CT and PET/MR)
The beginnings and development trends of positron emission tomography are outlined
in Table 4. Again, constraints on space prevent a detailed analysis. Suffice to say that
for a physician, interested in patient care and management, it took a rather long time
before clinical useful applications began to emerge [5-7]. It would take the development
and final availability of 18F labelled glucose, which made positron emission tomography
a clinically useful tool. Between the development of the first PET system in 1973 byFigure 3 David Kuhl (born in 1929, retired in 2011). Image taken during presentation of the 2009 Japan
Prize Award, attended by Emperor Akihito. This prestigious prize was introduced in 1985 to award scientists
who contribute to the development of science and technology.
Table 4 The history of PET
1951 First use of NaI probes for positron detection in brain William Sweet and
Gordon Brownell
1963 First description of radon equations for image reconstruction Alan M. Cormack
1973 Description of CT scanner Godfrey N. Hounsfield
First PET tomograph Michael E. Phelps
1976 First commercial PET scanner
1978 First BGO-based scanner Chris Thompson
1977 14C Deoxyglucose Louis Sokoloff
1978 18F Fluorodeoxyglucose Tatsuo Ido
1986 Present synthesis of FDG Kurt Hamacher
1984 Commercial cyclotron development
1997 FDA approves FDG as radiopharmaceutical
1998 PET/CT prototype David Townsend and
Ron Nutt
1999 Lutetium orthosilicate (LSO)
1999 Medicare reimburses for staging NSCLC, SPN, colorectal ca, HD and NHD,
melanoma, hibernating myocardium and TLE
2001 PET/CT in UK at INM/UCL
2002 Health technology assessments (HTA) begin
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have elapsed (Table 4).
To complete this brief review, we end with David Townsend, Ph.D., who gave us the
most significant development in medical imaging in the last 10 to 15 years. The PET/
CT prototype, attributed to Townsend and Nutt (Figure 4), then President of CPS In-
novations, was named by TIME Magazine as the medical invention of the year 2000. A
hugely impressive development, bringing human anatomy and biochemistry onto a
combined 3D map, this technology was instantly adopted by the medical community asFigure 4 David W Townsend (2nd left) and Ronald Nutt (2nd right). The IEEE Medal for Innovations in
Healthcare Technology was given to David W Townsend (2nd left) and Ronald Nutt (2nd right). Photograph
taken with Moshe Kam (IEEE President Elect, left) and Pedro Ray (IEEE President, right).
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today can bypass the availability of a PET/CT system for appropriate patient management.
What about PET/MR? Time will tell; its adoption by the medical community will
take much longer. But the input of physics computing and engineering will remain vital
for the future development of this innovative speciality. This will be ever more relevant
as the demands posed by multimodality imaging technologies and the need for true
quantitative and reproducible measurements are widely felt. This is especially relevant
in the increasing need for the monitoring of interventions, being medical, surgical or
pharmacological, applied to an individual patient. Whilst the overtly simplistic aims of
personalised medicine are being reassessed, patient specific interventions will grow,
and with it, the growth of physics in the field is assured.
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